All sessions, except workshops, will be recorded and available on demand after conference for 6 months
Note: The 2022 Program is still being finalized, here are the sessions and speakers that are confirmed so far.
Session Type: Workshop
Stream: CSEM
Location: Telus 108-109
Learning Objectives: Agenda
At the end of this session, participants will be able to:
1. Review basic embryology and cell lines of pituitary development.
2. Describe reproductive cycle physiology.
3. Discuss the manifestations and diagnosis of delayed puberty.
4. Identify the causes of endocrine hypertension.
5. Outline the etiologies of hypocalcemia.
6. Compare approaches and management strategies for hypertriglyceridemia
Session Type: Workshop
Stream: Indigenous Science & Content
Location: Glen 206
At the end of this presentation, participants will be able to:
1. Build understanding of our shared history as Indigenous and non-Indigenous peoplesby walking through pre-contact, treaty-making, colonialism and Indigenous resistance
2. Support critical self-reflexivity: learning about who we are, who we are in relationship to Indigenous peoples, how we were socialized, and how that informs the stereotypes and biases we hold. Further, taking time to understand the harms and violences of Indigenous specific racism in health care.
3. Increase awareness of the intersection between land sovereignty, access to land, Indigenous food practices, and the impact of past and present colonial policies on the health of Indigenous peoples.
4. Explore how to createan Indigenous Cultural Safety learning journey to support aligning oneself and one’s practice to the recommendations outlined within the Truth and Reconciliation Commission Calls to Action, the BC In Plain Sight Report, and the United Nations Declaration onthe Rights of Indigenous Peoples
Registration for this workshop is now open!
Moderator
Session Type: Workshop
Stream: Clinical care and education
Location:Glen 201
At the end of this presentation, participants will be able to:
1. Discuss the pros and cons of insulin pumps.
2. State the steps required for successful transition to insulin pumps.
3. Demonstrate programming a pump.
4. Discuss a case study applying learned knowledge.
Moderator
Session Type: Workshop
Stream: Clinical care and education
Location: Glen 203-204
At the end of this presentation, participants will be able to:
1. Interpret and discuss appropriate actions to address intimidating CGM reports.
2. Use available clinical tools to address advanced clinical scenarios, i.e. the pregnant woman and the athlete.
3. Apply these strategies into practice.
Session Type: Workshop
Stream: Clinical care and education
Location: Glen 202
At the end of this presentation, participants will be able to:
1. Learn how psychotherapeutically informed interventions can be introduced and integrated into diabetes education.
2. Practice a Dozen simple interventions in small groups.
3. Consider how to combine interventions for optimum coaching conversations.
4. Discover how two steps can make your intervention memorable and transformative.
Moderator
Session Type: Symposia
Stream: All
Location: Hyatt Imperial Ballroom
Illustrated by real-life cases, Canadian experts in the clinical use of diabetes technology will share their practical tips and top EUREKA revelations that have made them more efficient, effective and empathetic, in their work with people with type 1 and type 2 diabetes.
At the end of this session, participants will be able to:
1. Recognize how the evidence for rtCGM has rapidly changed the standard of care and clinical practice
2. Apply practical tips that help people with diabetes use rtCGM easily and effectively
3. Reflect on their clinical practice and share revelations and learnings with people living with diabetes
This session is codeveloped with CSEM and Dexcom and planned to achieve scientific integrity and balance. Dexcom provided an unrestricted educational grant.
Chair
Session Type: Plenary
Stream: All
Location: MacLeod
At the end of this presentation, participants will be able to:
1. Describe stories exploring inequities of health care when delivering diabetes care and discuss trauma informed care when supporting and treating chronic diseases.
2. Discuss the determinants of health and how we apply this to patient care.
3. Reflect on how our personal bias affects the care we deliver to Indigenous patients.
Moderator
Session Type: Concurrent
Stream: CSEM
Location: Telus 104-108
Moderator
Session Type: Concurrent
Stream: Clinical care and education
Location: MacLeod
At the end of this presentation, participants will be able to:
1. Describe diabetes distress from the perspective of type 1 diabetes in childhood and adolescence.
2. Identify potential underlying psychosocial drivers for diabetes self-management issues in children/adolescents and their families.
3. Recognize the role of transitions in diabetes treatment planning throughout childhood and adolescence.
At the end of this presentation, participants will be able to:
1. Develop awareness of emotional distress and well-being as overarching constructs.
2. Demonstrate understanding of the drivers of distress: problems of living based, disease-based, and psychopathology based.
3. Describe problems of living based distress in the context of COVID-19 and the use stress-management and resilience building interventions.
At the end of this presentation, participants will be able to:
1. Define what diabetes distress is.
2. Describe how to screen for diabetes distress in the clinic setting.
3. Learn how to explore the specific source and nature of diabetes distress.
At the end of this presentation, participants will be able to:
1. Recognize the range of psychiatric conditions commonly seen in people living with diabetes.
2. Discuss the management of diabetes in individuals living with co-morbid psychiatric conditions.
3. Outline which medications to preferentially use and which ones to avoid in treating psychiatric symptoms in people with diabetes.
Moderator
Session Type: Concurrent
Stream: Scientific
Location: Macleod A
At the end of this presentation, participants will be able to:
1. Review the challenges of living with diabetes and the potential for mental health issues.
2. Describe how patient-oriented research can inform the co-design and implementing an integrated care model.
3. Describe an equitable and accessible technology enabled collaborative care (TECC) program for diabetes and mental health conditions.
At the end of this presentation, participants will be able to:
1. Describe how existing provincial-level administrative data resources can be leveraged to develop and implement population health management for diabetic retinopathy screening
2. Discuss how patient-oriented use of administrative health data can be used to guide clinical care and to inform the co-design and implementation of integrated care models related to diabetic retinopathy screening
3. Explain how Patient Partners can guide the development of innovative programs for diabetic retinopathy screening
At the end of this presentation, participants will be able to:
1. Learn about an innovative patient-oriented approach to planning research questions that answer their urgent health concerns
2. Learn about patient-oriented use of health data to inform the co-design and implementing integrated care models
3. Learn how research teams can support patient/citizen-led research
Moderator
Session Type: Concurrent
Stream: Scientific
Location: Glen 201-204
At the end of this presentation, participants will be able to:
1. Provide an overview of some of the bioenergetic challenges to canonical models of glucose-stimulated insulin secretion.
2. Discuss new research that reconsiders how glucose is metabolically sensed in the beta-cell.
3. Explain how oscillations and compartmented metabolic cycles are required for appropriate glucose-stimulated insulin secretion.
At the end of this presentation, participants will be able to:
1. Describe mitochondrial dynamics play a critical role in determining the response of pancreatic beta cells to glucose.
2. Explain pancreatic beta cells are hetergeneous in their responses to stimulation and defective mitochodrial function impairs their connectivity to restrict insulin secretion.
3. Describe incretins bypass defects in mitochondiral function in beta cells in type 2 diabetes.
Moderator
Session Type: Concurrent
Stream: Scientific
Location: Hyatt-Imperial 5,7,9 + Corridor
At the end of this presentation, participants will be able to:
1. Discuss the concept that a significant portion of people in the early stages of type 2 diabetes have asymptomatic and often undiagnosed diastolic dysfunction.
2. Discuss the overlapping cardiac metabolic signatures between diabetes and heart failure.
3. Discuss whether early targeting of dysregulated cardiac energetics may be a novel approach to alleviate diastolic dysfunction and prevent HFpEF in diabetes.
Moderator
Session Type: Symposia
Stream: All
Location: Hyatt
Session Type: Concurrent
Stream: CSEM
Location: Telus 104-106
At the end of this presentation, participants will be able to:
1. Understand the role of nuclear imaging in the diagnosis and follow-up of neuroendocrine tumours
2. Discuss PRRT as it pertains to patient selection and treatment sequencing, side effects and outcomes. Briefly discuss other radioligand therapies, such as I-131 MIBG in the management of NET patients
3. Review emerging theranostic developments in NETs
Moderator
Session Type: Plenary
Stream: All
Location: Macleod Hall
At the end of this presentation, participants will be able to:
1. Review the history of obesity medicines.
2. Compare currently approved medicines for obesity.
3. Highlight the investigational pipeline of medical therapies for obesity.
Moderator
Session Type: Concurrent
Location: Glen 206
Session: Concurrent
Stream: Indigenous Science & Content, Clinical Care and Education
Location: Glen 201-204
1. Improving Equality in Outcomes for Indigenous Peoples with Type 2 Diabetes: Use of Special Authority Criteria.
2. Does the HNF-1a G319S variant in Anishininew communities confer a metabolic advantage to fasting?
3. Provincial Care Gaps in Frequency of Hemoglobin A1c Testing.
4. Rural Residence is Associated With a Delayed Trend Away From Sulfonylurea Use for Treatment Intensification of Type 2 Diabetes.
5. Inequities in Recurrent Admissions of Diabetic Ketoacidosis: Cause for Concern.
Moderator
Session Type: Concurrent
Stream: Clinical care and education
Location: Hyatt Imperial 5
At the end of this presentation, participants will be able to:
1. Understand the role of obesity pharmacotherapy in type 2 diabetes.
2. Understand the role of obesity pharmacotherapy in type 1 diabetes.
At the end of this presentation, participants will be able to:
1. Discuss the upstream approach: shifting our focus to treating obesity further upstream in T2DM.
Moderator
Session Type: Concurrent
Stream: Scientific
Location: MacLeod Hall
At the end of this presentation, participants will be able to:
1. Contrast the pathophysiology of bone disease and risk factors for fracture in Type 1 and Type 2 diabetes.
2. Evaluate fracture risk in people with Type 1 and Type 2 diabetes.
3. Discuss the prevention and treatment of diabetic bone disease.
At the end of this presentation, participants will be able to:
1. Provide on overview of cancer risk in people with diabetes in comparison with the general population.
2. Discuss the risk factors for cancer and the mechanisms behind increased risk in people living with diabetes.
3. Describe cancer screening recommendations to reduce cancer risk in people living with diabetes.
Moderator
Session Type: Concurrent
Stream: CSEM
Location: Telus 104-108
At the end of this presentation, participants will be able to:
1. Review evidence-based recommendations regarding the differentiation and assessment of disease activity, to aide in earlier diagnosis, classification, and treatment of Graves' orbitopathy.
2. Assess current evidence regarding the efficacy, safety, benefits, and limitations of conventional and new treatments for the treatment of Graves' orbitopathy.
3. Summarize best practices for treatment and referral that can improve the multidisciplinary co-management of patients with Graves' orbitopathy.
Moderator
Session Type: Concurrent
Stream: Indigenous Science & Content
Location: MacLeod A
At the end of this presentation, participants will be able to:
1. Creating awareness of the complexities of dealing with a diagnosis of diabetes.
2. Understanding the barriers in living with diabetes for an Indigenous person.
3. Improve understanding of Indigenous people who live with diabetes and the challenges they face.
Moderator
Session Type: Concurrent
Stream: CSEM
Location: Telus 104-108
At the end of this presentation, participants will be able to:
1. Recognize Active Surveillance as a management strategy for patients with low-risk thyroid cancer
2. Name appropriate selection criteria for active surveillance and indicators suggesting that the approach is no longer a viable strategy
3. Choose a collaborative and multidisciplinary approach, essential to the active surveillance strategy
At the end of this presentation, participants will be able to:
1. Highlight differences in presentation and outcome of advanced papillary thyroid carcinoma in children versus adults.
2. Discuss a rational approach to treatment planning and prioritization for children with advanced PTC.
3. Explore novel strategies for treatment of advanced PTC using RAI and systemic therapies.
At the end of this presentation, participants will be able to:
1. Discuss use of diagnostic tests in disease surveillance of low-risk papillary thyroid cancer treated with hemi-thyroidectomy (e.g. neck ultrasound, thyroglobulin measurement).
2. Discuss long-term TSH goals and consideration of levothyroxine treatment in low-risk papillary thyroid cancer treated with hemi-thyroidectomy.
3. Discuss some general survivorship concerns in low risk papillary thyroid cancer patients.
Moderator
Session Type: Concurrent
Stream: Clinical care and education
Location: MacLeod A
1. Reduction in 1-year mortality after a primary lower extremity amputation associated with diabetes or peripheral artery disease: What about the severity of the amputation?
2. Evaluating Health Disparities in a Pediatric Population with Type 1 Diabetes.
3. Addressing Diabetes Burden with Personalized Lifestyle and Habit Change Coaching.
4. Technology-Enabled Collaborative Care for Diabetes (TECC-D): Feasibility and Acceptability of a Disruptive Integrated Care Model.
5. Impact of Hybrid care on Care Delivery and Obstetrical Outcomes on Women with Gestational Diabetes.
6. Essential diabetes medicines and health outcomes in 127 countries.
Moderator
Session Type: Concurrent
Stream: Scientific
Location: Glen 206
1. Investigating Alpha and Beta Cell Phenotypes in Type 1 Diabetes.
2. Oxidative Stress and Early Cardiovascular Disease in Youth with Type 1 Diabetes: the CARDEA Study.
3. A Small Molecule Activator of Lyn Improves the Outcomes of Islet Transplantation In Mice.
4. Single-cell RNA Sequencing Reveals a Role for Reactive Oxygen Species and Peroxiredoxins in Fatty Acid-induced Rat ß-cell Proliferation.
Moderator
Session Type: Concurrent
Stream: Scientific
Location: Hyatt Imperial 5
At the end of this presentation, participants will be able to:
1. Understand the challenges of diabetes self-management when experiencing food insecurity.
2. Identify strategies to better support diabetes self-management among patients experiencing food insecurity.
3. Implement systematic changes to identify food insecurity and reduce barriers to accessing services for those experiencing food insecurity.
At the end of this presentation, participants will be able to:
1. Review what is known about the patient-healthcare practitioner relationship and corresponding patient outcomes.
2. Refresh skills on increasing therapeutic alliance in time-sensitive appointments.
3. Practice tangible counselling skills that empower people living with diabetes and prediabetes for self-directed change in diet and exercise behaviours.
Moderator
Session Type: Concurrent
Stream: Clinical care and education
Location: MacLeod Hall
At the end of this presentation, participants will be able to:
1. Describe how intermittent fasting is an example of a popular restrictive diet approach to managing type 2 diabetes and weight
2. Identify eating disorder behaviours and diabetes distress factors to consider when discussing nutrition interventions with people living with diabetes
3. Summarize how the principles of intuitive eating can be used to individualize type 2 diabetes nutrition care
At the end of this presentation, participants will be able to:
1. Describe a multidisciplinary approach to using low carb/high fat ketogenic diets.
2. Through case studies, Illustrate adjustments in medications that need to be considered.
3. Address potential benefits and concerns about ketogenic diets in the setting of type 2 diabetes.
Moderator
Session Type: Concurrent
Stream: Indigenous Science & Content
Location: Glen 201-204
Moderator
Session Type: Symposia
Stream: All
Location: Hyatt Imperial Ballroom
This presentation will investigate continuous glucose monitoring metrics and patterns, the impact of time in range.
At the end of this session, participants should be able to:
1. Describe the impacts of glycemic variability on patient lifestyle, activity and quality of life.
2. Describe the implications of recent time-in-range studies.
3. Communicate the use of continuous glucose monitoring with patients and a multidisciplinary care team.
This program was co-developed and planned by CSEM and Sanofi to achieve scientific integrity, objectivity, and balance. Sanofi provided an unrestricted educational grant.
Moderator
Session Type: Symposia
Stream: All
Location: Hyatt Imperial Ballroom
Kick off your morning with an energizing, co-developed, accredited program discussing the impact of early achievement of glucose targets and weight reduction on the progression of type 2 diabetes (T2D) and the potential of dual GIP/GLP-1 receptor agonist therapy.
Adiposopathy is a root cause of T2D, and higher percentages of weight loss are associated with improved rates of A1C lowering, diabetes remission, and other long-term patient outcomes. To date, standard management approaches have often fallen short in achieving weight loss and A1C targets and “upstream” control of adiposopathy has not been appropriately prioritized. Newer therapies (GLP-1 and dual GIP/GLP-1 receptor agonists) have demonstrated that early achievement of A1C targets and weight reduction can benefit the long-term health of patients who have T2D.
With Dr. Sue Pedersen as your host, you will hear from two other experts in diabetes care, Ms. Lori Berard and Ms. Lisa Maks, discussing the importance of early A1C control and weight reduction in T2D, and the mechanism of action, efficacy, safety, and tolerability of dual GIP/GLP-1 receptor agonist therapy for patients living with T2D. They will discuss integration into patient management and wrap up with an open Q&A session
Moderator
Session Type: Plenary
Stream: CSEM
Location: Macleod
At the end of this session, participants will be able to:
1. Properly assess cardiovascular risk in individual patients.
2. Identify opportunities and challenges to decrease cardiovascular risk.
3. Name emerging therapies aimed at reducing cardiovascular risk.
Moderator
Session Type: Concurrent
Stream: CSEM
Location: MacLeod Hall
At the end of this presentation, participants will be able to:
1. Review the diagnostic criteria for premature ovarian insufficiency and early menopause.
2. Develop an approach to hormonal management of POI.
3. Understand the specificity of hormonal treatment for this specific group.
At the end of this presentation, participants will be able to:
1. Describe the risks and benefits of hormone therapy in the older trans and non binary individual.
2. Appreciate the factors which contribute to the negative health outcomes specific to trans and nonbinary older adults.
3. Formulate a patient centred approach to providing gender affirming hormone therapy in the older trans and nonbinary older adult.
1. Review the diagnostic criteria for premature ovarian insufficiency and early menopause
2. Develop an approach to hormonal management of POI
3. Understand the specificity of hormonal treatment for this specific group
Moderator
Session Type: Concurrent
Stream: Scientific
Location: Glen 201-204
1. Discuss the current status of beta cell replacement therapy for the treatment of T1D.
2. Describe clinical trials of stem cell derived islets.
3. Understand new advances and technologies in stem cell-derived islet transplantation that improve graft function.
1. Describe microencapsulation technologies and their application to stem cell derived islets
2. Discuss the challenges related to manufacturing and robustness of stem cell derived products
3. Understand novel vascularization approaches to engineer bioartificial pancreas systems
Moderator
Session Type: Concurrent
Stream: Scientific
Location: Glen 206
At the end of this presentation, participants will be able to:
1. Describe how microfluidic devices, including islet-on-a-chip, are being used for the study of beta cell function.
2. Discuss recent studies that have used islet-on-a-chip to assess beta cell metabolism and function.
3. Describe how novel biosensors can be used to study beta cell metabolism and function.
At the end of this presentation, participants will be able to:
1. Learn about a new real-time ELISA assay that enables continuous insulin measurement.
2. Learn about a new transdermal technology for tracking diabetes in a wearable setting.
3. Learn about our future direction in developing next-generation diabetes technologies.
Moderator
Session Type: Concurrent
Stream: Indigenous Science and Content
Location: Macleod A
At the end of this presentation, participants will be able to:
1. Understand the National Indigenous Diabetes Association and the organization's initiatives.
2. Highlight the TRC Report on Health with Indigenous People.
3. Describe personal journey winning the fight with Type 2 Diabetes.
Moderator
Session Type: Concurrent
Stream: Clinical care and education
Location:Hyatt Imperial 5
At the end of this presentation, participants will be able to:
1. List the unique considerations for glycemic management in people living with diabetes and severe kidney dysfunction.
2. Name antihyperglycemic therapies that are safe to use in those with severe kidney dysfunction.
3. Adjust antihyperglycemic therapies in those with severe kidney dysfunction, including dialysis, to avoid adverse effects and hypoglycemia.
At the end of this presentation, participants will be able to:
1. Describe the pathophysiology of hyperfiltration in diabetic nephropathy and to link this to current screening guidelines.
2. Understand how SGLT2i address hyperfiltration in kidney disease.
3. Update existing knowledge of SGLT2i kidney outcomes with the newest literature and clinical trials.
At the end of this presentation, participants will be able to:
1. Become familiar with novel agents that slow nephropathy progression independent of glucose control.
2. Learn how to use different classes of drugs to slow nephropathy progression.
3. Describe adverse effects and their management of the novel class of nonsteroidal mineralocorticoid receptor antagonists.
Moderator
Session Type: Concurrent
Stream: Clinical care and education
Location: Telus 104-108
At the end of this presentation, participants will be able to:
1. Describe the impacts of pregnancy related disorders (including gestational diabetes) on a female’s future cardiometabolic health.
2. Identify simple postpartum vascular risk reduction strategies.
3. Understand the key roles that interdisciplinary clinicians play in improving cardiovascular health after pregnancy.
At the end of this presentation, participants will be able to:
1. Discuss associations of GDM and GH with paternal diabetes
2. Consider links between GDM and offspring outcomes.
3. Conceptualize APOs as family health indicator.
Moderator
Session Type: Symposia
Stream: All
Location: Hyatt Imperial Ballroom
At the end of this presentation, participants will be able to:
1. Utilize the Diabetes Canada Clinical Practice Guidelines to understand the role of GLP-1 RAs and the benefits of early initiation in patients with T2D and CV Risk
2. Identify clinical complexities in the initiation and use of GLP-1 RAs and examine solutions through interdisciplinary perspectives
3. Discuss potential use of current and emerging GLP-1RA-based therapies in T2D and beyond
This program was co-developed and planned by CSEM and Novo Nordisk to achieve scientific integrity, objectivity, and balance. Novo Nordisk provided an unrestricted educational grant.
Stream: CSEM
Location: Telus 104-108
At the end of this presentation, participants will be able to:
1. Describe the impact of bariatric surgery on skeletal and muscle outcomes
2. Summarize potential mechanisms involved in skeletal health after bariatric surgery
3. Propose preventative measures to minimize bone loss following bariatric surgery
At the end of this presentation, participants will be able to:
1. Recognize the importance of genetic testing in patients with pheochromocytomas and paragangliomas
2. Identify risk factors for recurrent disease in pheochromocytomas and paragangliomas
3. Discuss genetic components in primary aldosteronism
Moderator
Session Type: Plenary
Stream: Clinical care and education
Location: MacLeod Hall
1. Describe the new revision process for Diabetes Canada clinical practice guidelines.
2. Share the context, methods, recommendations and implementation tools for a new “Remission of type 2 diabetes” chapter, the first of its kind in Canada.
3. Outline recommendations from the two CPG chapter updates (mental health and hypoglycemia) and a new “Do-It-Yourself Automated Insulin Delivery in type 1 diabetes” position statement.
1. Describe the new Diabetes Canada "Remission of type 2 diabetes” chapter.
2. Discuss the concept of type 2 diabetes remission.
3. Understand the recommendations from the new “Remission of type 2 diabetes” chapter.
1. Discuss the highlights of a new “remission of type 2 diabetes” chapter, the first of its kind in Canada, along with an accompanying guide on remission for health-care providers.
1. Describe why a position paper on DIY AID is needed including current HCP and PWD perspectives on the technology
2. Review evidence that demonstrates DIY AID can deliver improved A1C, time in ranges and quality of life
3. Apply the legal and ethical framework that encourages clinicians to support patients using DIY AID
Moderator
Stream: All
Location: Glen 201-204
1. Implicit Weight and Racial Bias in Diabetes Prevention Program Coaches
2. Stem Cell-Derived, Fully Differentiated Islet Cells for Type 1 Diabetes
3. Improving Access to Culturally Safe Tele-Diabetes/Obesity Care: An Indigenous Community-led Partnership
4. How We Do It: Strategies for Being Active with Type 1 Diabetes – a Qualitative Study
5. Once-weekly Insulin Icodec Demonstrated Better Glycaemic Control vs Once-daily Insulin Degludec in Basal Insulin-Treated Type 2 Diabetes
Moderator
Session Type: Concurrent
Stream: CSEM
Location: Telus 104-108
At the end of this presentation, participants will be able to:
1. Describe the two most common ways to biochemically assess renin.
2. Learn the tools to convert renin activity and renin mass between multiple unit systems.
3. Define how renin measurement can be affected by medications and specimen handling.
At the end of this presentation, participants will be able to:
1. Recognize the genetic causes of adrenal hypertension.
2. Understand when and how to send for genetic testing.
3. Understand the basics of how to interpret the genetic test results and when to as for help from a medical geneticist.
Moderator
Session Type: Concurrent
Stream: Clinical care and education
Location: Macleod Hall
At the end of this presentation, participants will be able to:
1. Clinically assess a patient for sleep behaviors, sleep health and sleep disorders.
2. Initiate basic and important behavioral measures to improve sleep health.
3. Determine when a referral to a sleep specialist is necessary and important.
4. Articulate the limitations of community based CPAP company care.
Moderator
Session Type: Concurrent
Stream: Scientific
Location: Hyatt Imperial 5
At the end of this presentation, participants will be able to:
1. Differentiate between systemic and cellular (immune cell) metabolism and how this could relate to diabetes.
2. Describe key metabolic pathways that contribute to pro-inflammatory immune cell function.
3. Identify relevant techniques and approaches to adress changes in cellular metabolism in the context of diabetes research.
At the end of this presentation, participants will be able to:
1. Discuss the impact of hyperinsulinemia on immune function.
2. Describe how adaptive immune cells become activated during obesity and their contribution to type 2 diabetes.
3. Discuss how obesity-related insulin resistance reciprocally dysregulates adaptive immune function.
Moderator
Session Type: Concurrent
Stream: Clinical care and education
Location: Glen 201-204
At the end of this presentation, participants will be able to:
Outline key nutrition recommendations for bariatric surgery preparation and postop.
1. Highlight nutrition concerns and challenges.
2. Explain psychological screening practices.
3. Discuss supports and challenges.
At the end of this presentation, participants will be able to:
1. Understand the complexity and chronicity of obesity.
2. Identify appropriate mental health screens and how mental health affects bariatric surgery outcomes.
3. Identify the challenges of helping people change their relationship with food.
At the end of this presentation, participants will be able to:
1. Understand the complexity and chronicity of obesity and its effect on diabetes
2. Identify current baraitric surgery outcomes and futher research
3. Discuss the newest guidelines for metabolic obesity and contexulaize surgery's place in the treatment of obesity and diabetes
Moderator
Session Type: Concurrent
Stream: Indigenous Science and Content
Location: Macleod A
Moderator
Stream: Scientific
Location: Glen 206
1. Once-Weekly Semaglutide 2.4 mg Improved Glucose Metabolism and Prediabetes in Adults with Overweight/Obesity in the STEP 1 Trial.
2. Identifying Blood Biomarkers for Type 2 Diabetes Subtyping: A Report from the ORIGIN Trial.
3. Insulin-Sparing Effects of Oral Semaglutide: an Analysis of PIONEER 8.
4. Patterns of Metformin Use and A1C Trends among Patients with Incident Type 2 Diabetes.
5. Predicting Real-World Severe Hypoglycemia Risk in Diabetes (iNPHORM, USA).
Moderator
Stream: CSEM
Location: Telus 104-108
1. Prospective Evaluation of Molecular Testing of Indeterminate Thyroid Nodule Cytologies Following Diagnostic Pathway Optimization.
2. Severity of albuminuria increases risk of fragility fractures independent of eGFR: a population-based analysis.
3. Mechanisms of β-cell Proliferation in Response to Insulin Resistance during Puberty.
4. The Impact of Bariatric Surgery on Assisted Reproductive Technology Outcomes: A Systematic Review.
5. Adrenal Insufficiency: Investigating Prevalence and Healthcare Utilization Using Administrative Data.
6. Polycystic Ovary Syndrome is associated with Increased Incidence of Co-morbidities in a Canadian Population Cohort.
Moderator
Session Type: Concurrent
Stream: Scientific
Location: Hyatt Imperial 5
At the end of this presentation, participants will be able to:
1. Recognize the under-appreciated role of hyperglucagonemia in diabetes.
2. Identify the intracellular compartments in the alpha cell through which glucagon is transported.
3. Discuss how abnormal glucagon secretion may be associated with altered intracellular transport of glucagon.
At the end of this presentation, participants will be able to:
1. Describe the regulation of islet hormone secretion by somatostatin and the contribution of the delta cell to glucose homeostasis.
2. Identify the mechanisms by which the fatty-acid receptor regulates somatostatin secretion from the delta cell.
3. Define the regulation of somatostatin action by regulators of G protein signaling in islets.
Moderator
Session Type: Concurrent
Stream: Clinical care and education
Location: MacLeod Hall
At the end of this presentation, participants will be able to:
1. Understand the challenges encountered by immigrants to Canada with diabetes mellitus.
2. Discuss how to alleviate the impact of cultural barriers on following the Diabetes Canada guidelines.
3. Describe the impact and propose practical tips to manage diabetes and complications during religious fasting.
Moderator
Session Type: Symposia
Location: Hyatt Imperial Ballroom
At the end of this session, participants will be able to:
1. Recognize the heightened risk posed by elevated triglycerides in the patient with diabetes with concomitant risk factors or with ASCVD.
2. Examine the evidence reading the cardiovascular benefits of icosapent ethyl and its mechanisms of action.
3. Explain practical issues in patient selection and follow up when prescribing icosapent ethyl to patients with diabetes at increased CV risk.
This program was co-developed and planned by CSEM, CCRN (the Canadian Collaborative Research Network) and HLS Therapeutics to achieve scientific integrity, objectivity, and balance. HLS Therapeutics provided an unrestricted educational grant.
Moderator
Session Type: Concurrent
Stream: CSEM
Location: Telus 104-106
At the end of this presentation, participants will be able to:
1. Review how brown adipose tissue oxidizes fatty acids and carbohydrates.
2. Discuss mechanisms regulating brown adipose tissue function in obesity and diabetes.
3. Detail how brown adipose tissue may exert positive effects on blood glucose homeostasis.
At the end of this presentation, participants will be able to:
1. Review the definition of brown adipose tissue.
2. Detail the effect of brown adipose tissue in energy expenditure and energy substrate homeostasis in humans.
3. Discuss the dysregulation of this tissue functions in obesity and diabetes.
Moderator
Session Type: Concurrent
Stream: Indigenous Science and Content
Location: MacLeod A
At the end of this presentation, participants will be able to:
1. Gain an understanding of the Can-SOLVE CKD Network, Indigenous Initiatives and patient voices.
2. Recognize the role of the Indigenous Peoples' Engagement and Research Council (IPERC) and its' footprint in patient-oriented research
3. Understand the importance of Indigenous trainings as part of the Wabishki Bizhiko Skaanj Learning Pathway
Moderator
Session Type: Concurrent
Stream: Clinical care and education
Location: Hyatt Imperial 5
At the end of this presentation, participants will be able to:
1. Recognize the role of experiential avoidance and cognitive fusion in non-adherence.
2. Understand the objective of cognitive flexibility using acceptance, acceptance, mindfulness and cognitive defusion.
3. Identify key elements of parental support and the parent-adolescent relationship in treatment adherence and disease management.
At the end of this presentation, participants will be able to:
1. Describe advantages of CGM based on scientific evidence and reasons for early adoption.
2. List potential benefits of early adoption of CGM in pediatric population.
3. Generate ideas for implementation of early CGM use in your local clinic settings based on the McMaster experience.
Moderator
Session Type: Concurrent
Stream: Clinical care and education
Location: Glen 201-204
At the end of this presentation, participants will be able to:
1. Understand the importance and role of diabetic foot screening in a diabetes care setting.
2. Develop skills and knowledge on when and how to screen for diabetic foot diseases.
3. Understand how to apply a diabetic footcare pathway.
Moderator
Session Type: Concurrent
Stream: Scientific
Location: MacLeod Hall
At the end of this presentation, participants will be able to:
1. Assess the importance of residual hypoglycemic risk.
2. Identify the role of new technologies and therapeuthics to mitigate hypogklycemic risk.
3. Improve the tretament of residual episodes.
Moderator
Session Type: Plenary
Stream: Clinical care and education
Location: Macleod Hall
At the end of this presentation, participants will be able to:
1. Describe diabetes life lessons from the perspective of a high-performance athlete and researcher.
2. Discuss the importance of including the larger support network in the diabetes care team.
3. Analyze how and why diabetes management programs should be personalized to ensure suitability for individual lifestyle needs.
Moderator
Session Type: Concurrent
Stream: CSEM
Location: Telus 104-106
At the end of this presentation, participants will be able to:
1. Identify risk factors for drug resistant prolactinomas
2. Define drug resistance in prolactinomas
3. Describe management strategies for prolactinomas resistant to dopamine agonist therapy
At the end of this presentation, participants will be able to:
1. Detail the causes and characteristics of infiltrative disease affecting the pituitary.
2. Choose the appropriate investigations and indications for biopsy/surgery.
3. Discuss the appropriate management and use of glucocorticoids.
Moderator
Session Type: Concurrent
Stream: CSEM
Location: Telus 104-106
At the end of this presentation, participants will be able to:
1. Compare the benefits and risks of providing versus withholding perioperative corticosteroids to patients undergoing transsphenoidal pituitary surgery.
2. Identify nuances in certain cases that would make one approach more appropriate than the alternative approach.
3. Discuss their current practice with multi-disciplinary teams to ensure best practice is being followed within the specific context of each centre.
At the end of this presentation, participants will be able to:
1. Compare the benefits and risks of providing versus withholding perioperative corticosteroids to patients undergoing transsphenoidal pituitary surgery.
2. Identify nuances in certain cases that would make one approach more appropriate than the alternative approach.
3. Discuss their current practice with multi-disciplinary teams to ensure best practice is being followed within the specific context of each centre.
Moderator
Session Type: Concurrent
Location: MacLeod Hall
At the end of this presentation, participants will be able to:
1. Understand the evidence for diabetes prevention after GDM.
2. Describe the advantages and limitations of pharmacotherapy and lifestyle/behavioural interventions.
3. Compare pros and cons of pharmacotherapy versus lifestyle/behavioural interventions.
Moderator
Session Type: Concurrent
Stream: Scientific
Location: Glen 201-204
At the end of this presentation, participants will be able to:
1. Describe how muscle cells directly respond to excess saturated fat, affecting insulin signalling and beyond.
2. Explain how the body responds to excess saturated fat, with particular focus on innate immune cells.
3. Describe how immune cells in the bone marrow respond to high fat diets.
At the end of this presentation, participants will be able to:
1. Describe the mechanisms by which nutrient satiation promotes insulin resistance.
2. Discuss the role of inflammation in the development of insulin resistance.
3. Discuss novel targets (e.g. SHP-1) for potential insulin resistance therapies.
Moderator
Session Type: Concurrent
Stream: Clinical care and education
Location: Hyatt Imperial 5
1. Recognize that clinician burnout and diabetes distress have similar origins in the brain and the mind
2. Explore how both living with Diabetes and treating patients with a chronic illness leads to distress, disengagement and even burnout
3. Discover how a four-step process can help clinicians ease burnout, become more resilient and even experience quiet pervading joy in their work
4. Apply those same principles to patients with diabetes distress in your clinical practice using simple interventions taught in the workshop
Moderator
Session Type: Indigenous Science & Content
Session Type: Indigenous Science & Content
At the end of this session, participants will be able to:
1. Understand why it is scientifically invalid to state that Indigenous Peoples have higher rates of diabetes because of their genes.
2. Recognize the biological role that social stressors may play in influencing individual vulnerability to T2D.
3. Consider the role that social stressors may play in the higher rates of T2D observed among Indigenous Peoples.
Joanne Lewis is a registered dietitian and Director of Healthcare Provider Education and Engagement at Diabetes Canada where she has worked for more than seven years to help Canadians receive the best information possible. She is involved in developing resources and programs related to diabetes care and management, as well as the dissemination of the Diabetes Canada Clinical Practice Guidelines. Joanne has several years’ experience practising as a registered dietitian in diabetes clinical settings where she worked closely with patients and their families in managing their diabetes.